Concordant negative | Concordant positive | Discordant low | Discordant high | |||||
---|---|---|---|---|---|---|---|---|
HER2 -, H2T low | HER2 +, H2T high | HER2 +, H2T low | HER2 -, H2T high | |||||
Parameter | No. | % | No. | % | No. | % | No. | % |
Tumor size (cm) | ||||||||
<2 | 45 | 51% | 30 | 49% | 9 | 47% | 6 | 43% |
>2 | 43 | 49% | 31 | 51% | 10 | 53% | 8 | 57% |
Tumor grade | ||||||||
Grade 1 and Grade 2 | 41 | 54% | 10 | 19%* | 6 | 40% | 8 | 62% |
Grade 3 | 35 | 46% | 43 | 81% | 9 | 60% | 5 | 38% |
Stage at initial diagnosis | ||||||||
I and II | 73 | 83% | 40 | 65% | 14 | 74% | 8 | 47% |
III and IV | 15 | 17% | 22 | 35%* | 5 | 26% | 9 | 53% |
Nodal status at diagnosis | ||||||||
Node negative | 40 | 55% | 15 | 28% | 7 | 47% | 3 | 25% |
Node positive | 33 | 45% | 38 | 72% | 8 | 53% | 9 | 75% |
Hormone receptor (ER/PR) status | ||||||||
Negative | 19 | 21% | 23 | 37%* | 6 | 32% | 4 | 24% |
Positive | 72 | 79% | 40 | 63%* | 13 | 68% | 13 | 76% |